Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
Sophie A. Kurk(Utrecht University), Anne M. May(Utrecht University), Pim de Jong(University Medical Center Utrecht), Cornelis J.A. Punt(Utrecht University), Miriam Koopman(Utrecht University), Peter A. M. Kint(Amphia Ziekenhuis), Rebecca K. Stellato(University Medical Center Utrecht), Lieke H. J. Simkens(Academic Medical Center), Manuel L. R. Tjin‐A‐Ton(Ziekenhuis Rivierenland), Felix de Jongh(Ikazia Ziekenhuis), Petra H.M. Peeters(University Medical Center Utrecht), Bea C. Tanis(Leiden University Medical Center), Marion Jourdan(Nutricia Research (Netherlands)), Ankie Van Der Velden(Tergooi), Bram Dorresteijn(Nutricia Research (Netherlands)), Geert‐Jan Creemers, Frans Erdkamp
Cited by 107
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k